Technology — ODS
Implicit is developing the small molecule dipeptide oglufanide disodium (ODS) for a range of community and hospital-acquired infections. The mechanism of action of ODS avoids the challenge which the rapid mutation of these pathogens pose to antimicrobial drugs. Likewise, this mechanism accounts for the exceptionally broad spectrum of infections against which ODS has demonstrated efficacy, including various biowarfare agents. It also means that ODS may complement or synergise with current drugs, offering the possibility of superior clinical outcomes in severe cases, and extending the useful life of older drugs which have become less effective over time due to pathogen mutation.